Shire want to create Major Presence in Opthalmic Business
October 16, 2014
Good day. My name is Robert Dempsey. I’m the Vice President and Business Unit head of Ophthalmology for Shire. It’s a very exciting time for the organization as we recently announced the origination of a Business Unit, dedicated to the ophthalmic space. We are in the process of building our team, in which we are hiring folks for both commercial, research and development, as well as medical affairs, to be dedicated to the space.
I just had the opportunity to moderate the Pharma session. It was very, very exciting as we are looking for opportunities to enhance our portfolio; both early, mid- and late-stage opportunities for both the interior segment as well as [inaudible 00:00:37]segment. I’d have to say, with our opportunities the financial ability of Shire to be a major player, to have the opportunity to moderate and get to meet some of these leaders in the field, and the opportunity to collaborate with these individuals going forward would be very exciting.
So once again, thank you to OIS for the opportunity to moderate this session, and I look forward to having Shire become a major force in the ophthalmic space. Thank you.
----------------------------------------------------------------
Shire has since made a purchase of an opthalmic business:
Lexington, Mass. – August 3, 2015 – Shire plc (LSE: SHP, NASDAQ: SHPG) announced today that it has acquired New York-based, privately held Foresight Biotherapeutics Inc. for $300 million. With the acquisition, Shire acquires the global rights to FST-100 ... a therapy in late-stage development for the treatment of infectious conjunctivitis, an ocular surface condition commonly referred to as pink eye. This acquisition further strengthens Shire’s late-stage pipeline, has a clear strategic fit with lifitegrast, which is in late-stage development for treatment of dry eye disease, another ocular surface condition, and further demonstrates Shire’s commitment to building a leadership position in ophthalmics.
AI
